Equity Research
William Blair equity analyst Sami Corwin’s research note on pharmaceutical company uniQure N.V., maker of Hemgenix, a gene therapy for hemophilia b patients, is quoted in this MedCity Dive article on other biopharma companies engaged in gene therapy trials.
Her note said that “[William Blair]’s survey of U.S. physicians who treat hemophilia found that a weighted average of 36% of adult hemophilia B patients would be good gene therapy candidates.”
Stay up-to-date with the latest William Blair news and insights
William Blair acted as the exclusive financial advisor to Duomed Group, a portfolio company of G Square Healthcare Private Equity, in connection with the contemplated sale to Palex Medical, a portfolio company of Apax Partners and Fremman Capital.
Read moreAbsent further legislation, The Tax Cuts and Jobs Act will sunset on January 1, 2026, reverting to 2017 levels, adjusted for inflation, or approximately $7M per taxpayer. As a result, wealthy individuals and families will be subject to significantly more federal estate tax in 2026 than they are today.
Read moreUnderstanding the nuances between retirement plans can be challenging. William Blair’s Quick Reference Guide to Retirement Plans compares and contrasts features such as account establishment, account contributions, and accessibility.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
